PAB 12.5% 0.7¢ patrys limited

Ann: PAT-DX1 Clinical Target Indications Confirmed, page-148

  1. 16,259 Posts.
    lightbulb Created with Sketch. 742
    There is definitely buying going on , these low volume down days are buying opportunities imo.

    Current work being done -
    " Details of the cell line development program are currently being finalized, and the program will be initiated in coming weeks."
    There are no delays on anything imo.

    Yale University are no dummies have sold none of their 16 million plus shares.


    From annual report

    The past year has been particularly exciting for Patrys, and the Company has reported positive results from multiple pre-clinical cell and animal models. Highlights of these experiments include:
    • PAT-DX1 kills colon cancer cells that lack key DNA repair enzymes (BRCA2)
    • PAT-DX1 is active against primary human glioblastoma explants from patients
    • PAT-DX1 shows efficacy in animal model of triple negative breast cancer
    • PAT-DX1 synergizes with the PARP inhibitor olaparib in cell culture
    • PAT-DX1 crosses the blood brain barrier, reduces tumour size and increases survival in an orthotopic glioblastoma model
    • PAT-DX1 targets and kills glioblastoma cancer stem cells
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
-0.001(12.5%)
Mkt cap ! $14.40M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $43.28K 6.183M

Buyers (Bids)

No. Vol. Price($)
1 237374 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 1732079 8
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.